ADELAÏDE-GROUP
The Adelaide group, which includes Verlingue, Génération and Cocoon, has achieved €338 million in turnover in 2022, up 9.3%. These results are in line with its ambition of achieving a turnover of more than €400m by the end of the IMPACT 2024 Plan.
“In a consolidating industry, being a family-owned broker with a long-term vision allows us to pursue a strong growth, combining sustainability and profitability. We are proud of these results, which highlight the dedication of our teams,” states Jacques Verlingue, Chairman of the Adelaïde Group.
Specialising in corporate protection, Verlingue achieved a turnover of €239m this year, up 8.6%, of which 6% was organic growth. The broker also pursued its external growth with two acquisitions, Depeyre in France and RT Global Insurance in Portugal.
Génération, which specialises in the management of healthcare and personal protection benefits, is stepping up its momentum with a 13.8% growth rate (€86m in turnover).
Lastly, Cocoon, which specialises in the digital distribution of healthcare insurance products to private individuals, confirms its ambition with a stable turnover of €14m in 2022.
“2022 confirms that the Adelaide Group's growth is buoyant and controlled, in line with the 2024 strategic plan, with the aim of offering our customers even more added value,” says Gilles Bénéplanc, CEO of the Adelaïde Group.
Adelaïde reaffirms its ambition is to become a leading broker in Europe through its family-owned and independent model
The Adelaïde Group is implementing this European ambition through strong organic growth and acquisitions. Verlingue is consolidating its international position with an international turnover share of 29%. After five acquisitions in five years (Switzerland, France, United Kingdom, Portugal), Verlingue wishes to accelerate this trend in new geographical areas and new businesses.
“These results reflect the group's commitment to its European strategy. We have the ambition to continue to build on this momentum through new acquisitions in new countries as opportunities arise,” explains Benjamin Verlingue, Deputy CEO of the Adelaïde Group.
Controlled change in governance and ambitious recruitment
The excellent results for 2022 also support the business plan of the group, which is celebrating its 90th anniversary this year.
In 2024, the group's governance will evolve as Benjamin Verlingue will take over from Jacques Verlingue as Chairman. This handover is part of the continuity and the desire to preserve the group's spirit. Benjamin Verlingue will continue to step up the diversification and geographical expansion of the group’s operations.
In this context, the Adelaïde Group announces the appointment of Anne-Jacques de Dinechin as CEO of Verlingue. He will manage Verlingue with the aim of continuing to achieve profitable growth in each of its business segments.
Currently employing 2,200 people, Adelaïde aims to recruit 300 people by 2023.
About Adelaïde
The Adelaïde Group specialises in insurance consultancy, intermediation, distribution and management, with the aim of enabling its clients to run their businesses through effective risk management by helping them protect their operations and employees. Over the past 90 years, the Group has been tirelessly innovating, growing and reinventing itself to become one of the main players in insurance brokerage in France, with three successful companies to date: Verlingue, Génération and Cocoon. Organic growth, strategic acquisitions and international expansion and digital transformation are the four priorities that the Group has set itself to achieve its objective of building a large, family-owned and independent insurance brokerage group with a European dimension.
2,200 employees
€2,600 m in premiums negotiated
2.2 million policy holders (health and life insurance)
27 offices in France and Europe (the UK, Switzerland and Portugal)
www.adelaidegroup.fr
(*): growth based on proforma 2021 turnover
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230405005671/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical added to membership of Russell 3000® Index28.6.2025 01:30:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global franchise and provider of services for aesthetic clinics, has been added as a member of the broad-market Russell 3000® Index, effective after the US market opens on June 30, as part of the 2025 Russell indexes reconstitution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250608244276/en/ Yoshiyuki Aikawa-Director (Chairman), CEO Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000®Index as well as the appropriate growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to
Altimetrik and SLK Software Join Forces to Create an AI-First Engineering Services Powerhouse27.6.2025 22:44:00 CEST | Press release
Altimetrik, a pure-play AI, Data and Digital engineering solutions company, today announced the signing of a definitive agreement to acquire SLK Software (“SLK”), a global technology services firm focused on delivering AI, intelligence automation and analytics solutions. The acquisition will further strengthen Altimetrik’s end-to-end enablement services and expand its customer reach, with a clear path to accelerate towards Altimetrik’s goal of reaching $1billion in annual revenue. The transaction remains subject to customary closing conditions and is expected to close in the second half of 2025. Financial details were not disclosed. Founded in 2000, SLK is recognized as a leader in the tech industry, and for its commitment to create innovative digital solutions. This strategic acquisition will significantly enhance the scale of Altimetrik’s capabilities, bringing together Altimetrik’s AI-first, platform-native engineering model and SLK’s full technology services stack that will further
Andersen Consulting udvider sine kompetencer inden for forretningstransformation med tilføjelsen af The Clearing27.6.2025 16:48:00 CEST | Pressemeddelelse
Andersen Consulting udbygger sin platform med samarbejdsfirmaet The Clearing, som er en managementkonsulentvirksomhed med speciale i organisatorisk omstilling og lederudvikling. The Clearing blev stiftet i 2009 og rådgiver kunder om komplekse udfordringer ved at afstemme ledelse, strategi, kultur og drift. Firmaet arbejder med føderale agenturer, virksomheder og nonprofitorganisationer med henblik på at skabe målbare forandringer på tværs af forskellige interessenter til gavn for en leders vision og strategi. Med dyb erfaring inden for flere sektorer, herunder national sikkerhed, sundhedspleje og finansielle tjenester, leder The Clearings unikke blanding af talent med ekspertise inden for organisationsudvikling, dataanalyse og visuel rådgivning forretningstransformationer i stor skala og arbejder sammen med kunder og eksperter for at sikre, at rådgivning omsættes til implementering. "Vi leverer transformative resultater, der ikke kun er i overensstemmelse med strategiske mål, men også
PRD Therapeutics Announces Initiation of First-in-Human Study for PRD00127.6.2025 16:00:00 CEST | Press release
PRD Therapeutics, Inc., a clinical stage company focused on the development of novel lipid metabolism regulators targeting homozygous familial hypercholesterolemia (HoFH) and metabolic dysfunction associated fatty liver disease (MASH/MASLD), today announced that the company recently initiated dosing in a First-in-Human (FIH) clinical trial of PRD001, a first-in-class SOAT2 (formerly known as ACAT2) selective inhibitor. “We are excited to initiate dosing in this clinical trial of PRD001. Many clinical trials have been conducted on SOAT1/2 dual or SOAT1 selective inhibitors, but this is the first clinical trial of an SOAT2 selective inhibitor” said Kanji Hosoda, Ph.D., CEO and co-founder of PRD Therapeutics. “Several results with SOAT1 or 2 knockout mice have been published, suggesting that knocking out or inhibiting only SOAT2 is crucial to demonstrate safety and efficacy. PRD001 is the world's first and only SOAT2-selective inhibitor and is expected to exhibit safety and efficacy in hu
STEMCELL Technologies Introduces STEMprep™ Tissue Dissociator System to Accelerate Research Discoveries27.6.2025 14:00:00 CEST | Press release
New instrument automates tissue processing for researchers in cancer, immunology and other science fields To help scientists accelerate their workflows, STEMCELL Technologies has commercially launched the STEMprep™ Tissue Dissociator System—a new benchtop instrument that automates, standardizes, and streamlines tissue dissociation, the process of breaking down tissue samples into single-cell suspensions for research purposes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250627342791/en/ To help scientists accelerate their workflows, STEMCELL Technologies has commercially launched the STEMprep™ Tissue Dissociator System—a new benchtop instrument that automates, standardizes, and streamlines tissue dissociation, the process of breaking down tissue samples into single-cell suspensions for research purposes. “Tissue dissociation is incredibly important for making advancements in research fields, like cancer and immunology, yet
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom